首页TY-JOURT1-小脑膜炎光谱失常JF-神经学JO-神经学SP-e985LP-e994DO-101212/WNL.000000011625VL-100IS-9AU-RaffaellaPizsolatoUA-MichaelWaltzAU-GregorySAaenAU-Leslie BensonAU-MarkGormanAU-ManuGoyalAU-JenniferS格雷夫斯AU-约兰达哈里斯AU-劳伦克鲁普AU-TimothyELotseAU-NikitaM首页Shukla AU - Soe Mar AU - Jayne Ness AU - Mary Rensel AU - Teri Schreiner AU - Jan-Mendelt Tillema AU - Shelly Roalstad AU - Moses Rodriguez AU - John Rose AU - Emmanuelle Waubant AU - Bianca Weinstock-Guttman AU - Charles Casper AU - Tanuja Chitnis AU - on behalf of the US Network of Pediatric MS Centers Y1 - 2023/02/28 UR - //www.ez-admanager.com/content/100/9/e985.abstract N2 - Background and Objective Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune condition, which can lead to significant disability, and up to 3%–5% of the cases have a pediatric onset.有限研究指导医生对NMOSD儿童进行疾病调控选择。案例分类为aqportroyte glycotein抗体负值初始DMTs包括Rituximab、icophenolate、azatioprine和IV免疫球素对年化复发率的影响经负二分回归评估时间递增EDSS增分QP4+和14DS模型模拟Cox比例风险模型 Results共识别91名NMOSD儿童:77AQP4+和14DS(85.7%女性!白人43.2%和非裔46.6%81名病人开始DMT测试,10名病人在分析时天真处理ARR计算所有血清组数为0.25(95%CI0.13-0.49)、0.33(95%CI0.19-0.58)、0.40(95%CI0.13-1.24)athioprine和0.54(95%CI0.28-1.04)。AQP4+分组为0.28(95%CI0.14-0.55)、0.39(95%CI0.21-0.70)、ephenolate、0.41(95%CI0.13-1.29)athioprine和0.54(95%CI0.23-1.26)。ARR类处理在所有血清组为0.97(95%CI0.58-1.60),AQP4+分组为0.91(95%CI0.53-1.56)。初始DMT对EDSS进化无统计意义作用 讨论使用DMTs, 特别是rituximab与NMOSDAQP4+.CliscriptationDAC=Data协调分析中心DMTs=disease-modifying treatments!EDSS扩展残疾状况尺度LETM长姿态广跨子膜炎MS多分解NMOSD=神经膜炎选择频谱失序ER-